Fluoguide AS Market Cap ($53.66 Million)
Market Cap & Net Worth: Fluoguide AS (FLUO)
Fluoguide AS market cap. Fluoguide AS (ST:FLUO) has a market capitalization of $53.66 Million (Skr498.65 Million) as of November 3, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #21468 globally and #396 in its home market, demonstrating a -1.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fluoguide AS's stock price Skr30.50 by its total outstanding shares 16349313 (16.35 Million). Also see cash flow conversion of Fluoguide AS for how efficiently the company converts equity into cash flow.
Fluoguide AS Market Cap History (2019–2026)
Fluoguide AS market cap history from 2019 to 2026. Data shows growth from $13.52 Million to $53.66 Million (16.85% CAGR). Check FLUO stock price for real-time trading data and today's change.
Index Memberships
Fluoguide AS is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.32 Billion | 0.35% | #58 of 281 |
Weight: Fluoguide AS's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Fluoguide AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fluoguide AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Fluoguide AS to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
178.92x
Fluoguide AS's market cap is 178.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $150.96 Million | $9.61 Million | -$23.77 Million | 15.70x | N/A |
| 2022 | $65.98 Million | $6.51 Million | -$27.34 Million | 10.13x | N/A |
| 2023 | $107.68 Million | $423.00K | -$38.38 Million | 254.56x | N/A |
| 2024 | $68.88 Million | $385.00K | -$28.96 Million | 178.92x | N/A |
Competitor Companies of FLUO by Market Capitalization
Companies near Fluoguide AS in the global market cap rankings as of November 3, 2026. Also see FLUO asset base for a full breakdown of the balance sheet.
Key companies related to Fluoguide AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Fluoguide AS (2019–2026)
Market capitalization of Fluoguide AS from 2019 to today. Between 2019 and today, Fluoguide AS's market cap moved from $13.52 Million to $ 53.66 Million, with a yearly change of 16.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr53.66 Million | -11.08% |
| 2025 | Skr60.35 Million | -12.39% |
| 2024 | Skr68.88 Million | -36.03% |
| 2023 | Skr107.68 Million | +63.20% |
| 2022 | Skr65.98 Million | -56.29% |
| 2021 | Skr150.96 Million | -27.96% |
| 2020 | Skr209.56 Million | +1449.57% |
| 2019 | Skr13.52 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of Fluoguide AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.66 Million USD |
| MoneyControl | $53.66 Million USD |
| MarketWatch | $53.66 Million USD |
| marketcap.company | $53.66 Million USD |
| Reuters | $53.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fluoguide AS
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical T… Read more